The most useful thing about a major new review of protein and aging is not its conclusion, which remains contested, but the frame it gives the entire argument. Bailey Knopf and Dudley Lamming of the University of Wisconsin-Madison have organized more than 350 studies into a list of six hallmarks of protein restriction, the first attempt to systematize a literature that has been pulling in opposite directions for decades. Their organizing idea is that protein is not simply a nutrient with an optimal dose. It is a growth signal, and the body’s response to that signal depends on what the body is doing with it.
The timing could not be more pointed. Official advice has been drifting upward: the RDA stands at 0.8 grams of protein per kilogram of body weight, experts recommend 1.0 to 1.2 grams for adults over 65 to protect against frailty, and the most recent Dietary Guidelines for Americans set the target range at 1.2 to 1.6 grams, nearly double the old minimum. Consumers have followed. The review notes that 61 percent of American consumers reported increasing their protein intake in 2024, up from 48 percent in 2019, as food companies rushed to fortify products. Meanwhile, a separate body of evidence, mostly observational, associates high-protein diets with higher rates of diabetes, cancer, and cardiovascular mortality. Both cannot be the whole story, and the review is an attempt to explain why.
The explanation begins with how cells read amino acids. The mechanistic core of the review is that protein acts through three interlocking sensors. The first is mTORC1, a protein complex that functions as a growth command center: amino acids, particularly the branched-chain amino acids leucine, isoleucine, and valine, activate it, and activation drives the cellular machinery that builds muscle and other tissue. Protein restriction turns the signal down, and the review emphasizes that without mTORC1 inhibition, the benefits of restriction disappear in mouse models. The second sensor is GCN2, which detects amino acid scarcity directly: when transfer RNAs sit empty, GCN2 phosphorylates a translation factor and shifts the cell toward stress-response and autophagy genes. The third is a hormone rather than a cellular sensor. FGF21 rises sharply when protein is restricted in mice, rats, and humans, and it appears to be required for nearly every benefit of restriction. Mice engineered to lack Fgf21 do not live longer on a low-protein diet, while mice overexpressing the gene live about 30 percent longer if male and 40 percent longer if female. FGF21 also drives the beiging of white fat, energy-burning tissue that helps explain a strange experimental result: animals and people on low-protein diets often eat more, yet lose fat and improve blood sugar.
That result has now been reproduced in humans, at least in short trials. In one 2016 study, 43 days of a low-protein diet decreased body weight, fat mass, and fasting glucose even though participants ate more calories. A five-week trial in lean young men found improved insulin sensitivity and higher energy expenditure. A 27-day trial in metabolic syndrome patients reported reduced adiposity and better insulin sensitivity. Animal data fill in the longevity picture: protein restriction extends lifespan in mice by roughly 10 to 35 percent and in rats by 13 to 53 percent, with larger effects in flies and even trout.
None of this means protein is harmful, and the review is careful to say so. The central caveat is context. When protein is eaten by someone whose muscles are being loaded by exercise, the amino acids are used to build tissue. When it is eaten by someone sedentary, the surplus can keep growth signaling running without any growth to do, and the review and its commentators argue this is where excess protein may accelerate the molecular damage that accumulates with age. Most Americans average only about 20 minutes of exercise a day, so for the majority of the population the sedentary case is the relevant one. The authors also stress that restriction is not for everyone: pregnant women, growing children, the elderly who are already protein-deficient, people recovering from injury, and anyone eating too few calories should not cut protein, and exercisers may need more than the guidelines suggest.
The review’s weaknesses are the field’s weaknesses. There are no long-term human trials of protein restriction, the observational studies linking high protein to mortality are confounded by diet quality, and the human evidence for benefit is mostly short and small. Nutrition researchers quoted in the Science News coverage of the review say the evidence is now sufficient to warrant trials, but not yet sufficient to write guidelines. What the hallmarks framework does accomplish is to give the debate a shared map: six mechanisms, from metabolic health to mitochondrial function to the epigenome, that restriction appears to act through. The next question is which of them matter most in people.
The practical resolution may be gentler than the debate suggests. Both the pro-protein and the anti-protein camps agree that recommendations should be personalized by age, sex, genetics, and activity level. The review’s deeper contribution is conceptual: the same amino acids that tell the body to grow may accelerate aging when that signal has no work to do. That framing turns the protein question from how much to eat into what the body is being asked to do with what it eats.
References
Bailey A. Knopf and Dudley W. Lamming, The hallmarks of protein and amino acid restriction in aging and longevity. Cell Press Blue (2026). DOI: 10.1016/j.cpblue.2026.100079.
Sujata Gupta, The protein craze may not be for everyone. Science News, 31 July 2026.
S.Q. Kim et al., Protein-restricted diets and their impact on metabolic health and aging. Annual Review of Nutrition 45 (2025). DOI: 10.1146/annurev-nutr-121624-114918.
Mariah F. Calubag et al., Lifelong restriction of dietary valine has sex-specific benefits for health and lifespan in mice. Nature Aging (2026). DOI: 10.1038/s43587-026-01169-0.